1. Home
  2. OBDE vs AKRO Comparison

OBDE vs AKRO Comparison

Compare OBDE & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OBDE
  • AKRO
  • Stock Information
  • Founded
  • OBDE 2020
  • AKRO 2017
  • Country
  • OBDE United States
  • AKRO United States
  • Employees
  • OBDE N/A
  • AKRO N/A
  • Industry
  • OBDE
  • AKRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • OBDE
  • AKRO Health Care
  • Exchange
  • OBDE NYSE
  • AKRO Nasdaq
  • Market Cap
  • OBDE 1.8B
  • AKRO 2.1B
  • IPO Year
  • OBDE N/A
  • AKRO 2019
  • Fundamental
  • Price
  • OBDE $14.55
  • AKRO $31.59
  • Analyst Decision
  • OBDE Buy
  • AKRO Strong Buy
  • Analyst Count
  • OBDE 1
  • AKRO 7
  • Target Price
  • OBDE $16.00
  • AKRO $43.20
  • AVG Volume (30 Days)
  • OBDE 180.0K
  • AKRO 441.5K
  • Earning Date
  • OBDE 11-06-2024
  • AKRO 11-11-2024
  • Dividend Yield
  • OBDE 4.03%
  • AKRO N/A
  • EPS Growth
  • OBDE N/A
  • AKRO N/A
  • EPS
  • OBDE N/A
  • AKRO N/A
  • Revenue
  • OBDE N/A
  • AKRO N/A
  • Revenue This Year
  • OBDE N/A
  • AKRO N/A
  • Revenue Next Year
  • OBDE N/A
  • AKRO N/A
  • P/E Ratio
  • OBDE N/A
  • AKRO N/A
  • Revenue Growth
  • OBDE N/A
  • AKRO N/A
  • 52 Week Low
  • OBDE $13.60
  • AKRO $11.36
  • 52 Week High
  • OBDE $16.80
  • AKRO $37.00
  • Technical
  • Relative Strength Index (RSI)
  • OBDE 55.89
  • AKRO 66.34
  • Support Level
  • OBDE $14.16
  • AKRO $29.34
  • Resistance Level
  • OBDE $14.65
  • AKRO $32.15
  • Average True Range (ATR)
  • OBDE 0.20
  • AKRO 1.26
  • MACD
  • OBDE 0.01
  • AKRO 0.10
  • Stochastic Oscillator
  • OBDE 80.33
  • AKRO 99.74

About OBDE BLUE OWL CAPITAL CORP III

Blue Owl Capital Corp III is focused on originating and making loans to, and debt and equity investments in middle-market companies based predominantly in the United States. Its objective is to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns. The company invests in senior secured or unsecured loans, subordinated loans or mezzanine loans and, to a lesser extent, equity and equity-related securities including warrants, preferred stock and similar forms of senior equity, which may or may not be convertible into a portfolio company's common equity.

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Share on Social Networks: